Literature DB >> 35304173

Optogenetic manipulations of CeA-CRF neurons modulate pain- and anxiety-like behaviors in neuropathic pain and control rats.

Mariacristina Mazzitelli1, Vadim Yakhnitsa1, Benjamin Neugebauer1, Volker Neugebauer2.   

Abstract

The amygdala plays a critical role in the emotional-affective component of pain and pain modulation. The central nucleus of amygdala (CeA) serves major output functions and has been linked to pain-related behaviors. Corticotropin releasing factor (CRF) in the CeA has emerged as an important modulator of pain and affective disorders. Here we measured the effects of optogenetic manipulation of CeA-CRF neurons on pain-related behaviors in a rat neuropathic pain model and under control conditions. Emotional-affective behaviors (vocalizations), mechanosensitivity (electronic von Frey anesthesiometer and calibrated forceps), and anxiety-like behaviors (open field test and elevated plus maze) were assessed in adult rats 1 week and 4 weeks after spinal nerve ligation (SNL model) and sham surgery (control). For optogenetic silencing or activation of CRF neurons, a Cre-inducible viral vector encoding enhanced halorhodopsin (eNpHR3.0) or channelrhodopsin 2 (ChR2) was injected stereotaxically into the right CeA of transgenic Crh-Cre rats. Light of the appropriate wavelength (590 nm for eNpHR3.0; 473 nm for ChR2) was delivered into the CeA with an LED optic fiber. Optical silencing of CeA-CRF neurons decreased the emotional-affective responses in the acute and chronic phases of the neuropathic pain model but had anxiolytic effects only at the chronic stage and no effect on mechanosensitivity. Optogenetic activation of CeA-CRF neurons increased the emotional-affective responses and induced anxiety-like behaviors but had no effect on mechanosensitivity in control rats. The data show the critical contribution of CeA-CRF neurons to pain-related behaviors under normal conditions and beneficial effects of inhibiting CeA-CRF neurons in neuropathic pain.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amygdala; Behavior; CRF; Neuropathic pain; Optogenetics

Mesh:

Substances:

Year:  2022        PMID: 35304173      PMCID: PMC9352141          DOI: 10.1016/j.neuropharm.2022.109031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.273


  51 in total

1.  NMDA receptor-independent synaptic plasticity in the central amygdala in the rat model of neuropathic pain.

Authors:  Ryo Ikeda; Yukari Takahashi; Kazuhide Inoue; Fusao Kato
Journal:  Pain       Date:  2006-10-19       Impact factor: 6.961

2.  Corticotropin-releasing factor in the caudal pontine reticular nucleus mediates the expression of fear-potentiated startle in the rat.

Authors:  M Fendt; M Koch; H U Schnitzler
Journal:  Eur J Neurosci       Date:  1997-02       Impact factor: 3.386

3.  Hemispheric lateralization of pain processing by amygdala neurons.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  J Neurophysiol       Date:  2009-07-22       Impact factor: 2.714

4.  Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal.

Authors:  G P McNally; H Akil
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

5.  Divergent functions of the left and right central amygdala in visceral nociception.

Authors:  Katelyn E Sadler; Neal A McQuaid; Abigail C Cox; Marissa N Behun; Allison M Trouten; Benedict J Kolber
Journal:  Pain       Date:  2017-04       Impact factor: 7.926

6.  Monomethyl fumarate inhibits pain behaviors and amygdala activity in a rat arthritis model.

Authors:  Hyunyoung Kim; Jeremy Thompson; Guangchen Ji; Vadivel Ganapathy; Volker Neugebauer
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

7.  Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain.

Authors:  Jeremy M Thompson; Guangchen Ji; Volker Neugebauer
Journal:  Mol Pain       Date:  2015-08-28       Impact factor: 3.395

Review 8.  Optogenetics: 10 years of microbial opsins in neuroscience.

Authors:  Karl Deisseroth
Journal:  Nat Neurosci       Date:  2015-09       Impact factor: 24.884

9.  Nasal application of neuropeptide S inhibits arthritis pain-related behaviors through an action in the amygdala.

Authors:  Georgina Medina; Guangchen Ji; Stéphanie Grégoire; Volker Neugebauer
Journal:  Mol Pain       Date:  2014-05-29       Impact factor: 3.395

10.  A Transgenic Rat for Investigating the Anatomy and Function of Corticotrophin Releasing Factor Circuits.

Authors:  Matthew B Pomrenze; E Zayra Millan; F Woodward Hopf; Ronald Keiflin; Rajani Maiya; Angelo Blasio; Jahan Dadgar; Viktor Kharazia; Giordano De Guglielmo; Elena Crawford; Patricia H Janak; Olivier George; Kenner C Rice; Robert O Messing
Journal:  Front Neurosci       Date:  2015-12-24       Impact factor: 4.677

View more
  3 in total

1.  Sex Differences in CGRP Regulation and Function in the Amygdala in a Rat Model of Neuropathic Pain.

Authors:  Peyton Presto; Volker Neugebauer
Journal:  Front Mol Neurosci       Date:  2022-06-03       Impact factor: 6.261

2.  Kappa Opioid Receptor Blockade in the Amygdala Mitigates Pain Like-Behaviors by Inhibiting Corticotropin Releasing Factor Neurons in a Rat Model of Functional Pain.

Authors:  Vadim Yakhnitsa; Guangchen Ji; Matthew Hein; Peyton Presto; Zack Griffin; Olga Ponomareva; Edita Navratilova; Frank Porreca; Volker Neugebauer
Journal:  Front Pharmacol       Date:  2022-05-25       Impact factor: 5.988

3.  Gingerol-Enriched Ginger Supplementation Mitigates Neuropathic Pain via Mitigating Intestinal Permeability and Neuroinflammation: Gut-Brain Connection.

Authors:  Chwan-Li Shen; Rui Wang; Vadim Yakhnitsa; Julianna Maria Santos; Carina Watson; Takaki Kiritoshi; Guangchen Ji; Abdul Naji Hamood; Volker Neugebauer
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.